RVRC Revium Rx.
Pharmaceutical Preparations · OTC · SEC CIK 1839140 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets22.4%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 |
|---|---|
| Income statement | |
| Revenue | — |
| Income tax | $358,000 |
| Net income | -$13.45M |
| EPS (basic) | -0.22 |
| EPS (diluted) | -0.22 |
| Weighted avg. shares (diluted) | 60.73M |
| Balance sheet | |
| Cash & equivalents | $1.68M |
| Current assets | $3.10M |
| PP&E, net | $10,000 |
| Goodwill | $2.58M |
| Intangibles | $2.50M |
| Total assets | $8.30M |
| Current liabilities | $799,000 |
| Total liabilities | $1.42M |
| Shareholders' equity | $6.88M |
| Shares outstanding | 60.73M |
| Cash flow statement | |
| Operating cash flow | — |
| Stock-based compensation | $624,000 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.